Yifei Sun

Yifei Sun

Auto-generated profile, based on publicly available information

Yifei Sun

Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Operative Neurosurgery
Verified
Journal Article
Closed access
YSYifei Sun
Yifei Sun
NLNicholas M.B. Laskay
Nicholas M.B. Laskay
GTGarrett W. Thrash
Garrett W. Thrash
SHSasha Howell
Sasha Howell
JMJames H. Mooney
James H. Mooney
JGJake Godzik
Jake Godzik
BACKGROUND AND OBJECTIVES: With an aging population, the prevalence of spine pathology including degenerative spine disease continues to increase. These pathologies present a significant disease burden, often requiring long-term and expensive care. Recent literature has linked several socioeconomic determinants of health with outcomes after spine surgery. We sought to conduct a systematic review to determine the relationship between Area Deprivation Index (ADI), a measure of neighborhood-level socioeconomic status, and objective and patient-reported outcome (PRO) measures after spine surgery and to propose potential interventions. METHODS: An Embase and Medline search was conducted from inception to April 1st, 2024, for relevant articles assessing ADI and spine surgery outcomes. The inclusion criteria were all North American observational studies available in English that reported on the association of ADI and adult cervical, lumbar, neoplastic, or deformity spine surgery outcomes. RESULTS: Ten articles met the inclusion criteria resulting in a combined 56 925 patients who had undergone elective surgery for cervical, lumbar, spine metastases, and adult spine deformity pathologies. Two studies reported ADI to be associated with increased costs of care and postoperative lengths of stay after cervical spine surgery. Five studies found the association between high ADI with increased rates of respiratory failure, 90-day emergency room visits, longer lengths of stay, 90-day reoperation rates, and poor PROs after lumbar spine surgery. One study found an association with high ADI and increased 30-day and 90-day readmissions across all spine surgeries, and 1 study found no association between ADI and overall survival after surgery for spinal metastases. CONCLUSION: Across available literature, high ADI seems to be associated with higher rates of postoperative readmissions and worse PROs. Further studies are needed to better understand the mechanisms underlying the effects of ADI on spine surgery outcomes and identify possible interventions to optimize outcomes.

6 January 2025 in Neuro-Oncology Advances
Verified
Journal Article
Open access
YSYifei Sun
Yifei Sun
MHMohammad Hamo
Mohammad Hamo
TATravis Atchley
Travis Atchley
BNBurt Nabors
Burt Nabors
JMJames Markert
James Markert
DEDagoberto Estevez-Ordonez
Dagoberto Estevez-Ordonez
Symptoms of depression are highly prevalent among patients with glioblastoma and have been associated with poor outcomes. In addition to managing depression symptoms, preclinical and clinical studies suggest that antidepressants may inhibit glioblastoma progression However, the effect of antidepressants on survival is unknown and results from existing studies are conflicting. We conducted a systematic review and meta-analysis to investigate the effect of antidepressant therapy on glioblastoma survival. We queried PubMed, Embase, Scopus, PsycINFO, and Web of Science from inception to March 2024 for studies investigating the overall survival of patients with glioblastoma treated with antidepressants. Results were combined using a restricted maximum-likelihood estimation random effects model. We identified 6 observational studies meeting inclusion criteria with 8,269 patients. Of these, 1,093 (13%) were treated with antidepressant therapy at some point after their glioblastoma diagnosis. Antidepressant therapy was not significantly associated with overall survival (HR 1.27, 95% CI 0.90–1.79, P = .17). In a subanalysis of studies that specified whether selective serotonin reuptake inhibitors were utilized, SSRI usage specifically was also not associated with overall survival (HR 1.08, 95% CI 0.58–2.03, P = .81). We observed considerable heterogeneity (I2 = 92.7%, P < .001). Antidepressants were not significantly associated with overall survival in patients with glioblastoma. However, our meta-analysis was limited by significant heterogeneity observed across studies. The effect of antidepressants on outcomes in patients with glioblastoma remains uncertain. We observed conflicting results in the literature, with some studies suggesting decreased survival. Therefore, the role of antidepressants in patients with glioblastoma warrants further investigation.